SANTA ROSA, Oct. 5 /PRNewswire/ — Osseon Therapeutics, Inc.
announced its new Osseoflex DR Steerable Bone Drill at the North
American Spine Society’s (NASS) annual meeting in Orlando, Florida.
The physician-controlled drill was designed to facilitate
treatment of vertebral compression fractures (VCFs) that may
contain sclerotic bone resulting from osteoporosis or fibrotic
metastases. The Osseoflex DR Steerable Bone Drill features
proprietary technology and allows for unipedicular access to
fractures previously considered inaccessible due to dense,
sclerotic bone or malignant bone tissue.
“Osseoflex DR is an innovation in VCF therapy. It provides an
important tool for cases where VCF needles and balloons are
currently inadequate,” said John Stalcup, Ph.D., Osseon’s President
and CEO. According to Michael T. Lyster, M.D., Chief Medical
Officer, “The Osseoflex DR Steerable Bone Drill further extends our
clinical reach beyond purely acute VCFs. We can now access
chronic and sub-acute symptomatic bone fractures throughout the
axial skeleton.”
Osseon markets the Osseoflex® Steerable Needle and
Osseoperm® Bone Cement for the treatment of vertebral
compression fractures. Together, they form the Osseoplasty
System which represents a safe and effective method for the
treatment of VCFs.
About Osseon
Osseon Therapeutics, Inc. focuses on bringing to market
alternative minimally invasive treatments for degenerative bone and
joint disease. Headquartered in Santa Rosa, CA, the company’s
groundbreaking technology and delivery system provides comparable
or better efficacy and safety than other commercial solutions while
offering significant advantages in efficiency and cost. By
improving the treatment of compression fractures within the
thoracic and lumbar vertebral spine, Osseon offers alternative
solutions to patients suffering from these maladies, as well as the
physicians and medical facilities t
‘/>”/>
